Mirikizumab in patients with ulcerative colitis – cases from clinical practice
Authors:
M. Lukáš 1; D. Bettenworth 2; V. Zacharová 1
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty, Klinické centrum ISCARE a. s. a 1. LF UK v Praze
1; CED Schwerpunktpraxis Münster, Münster, Deutschland
2
Published in:
Gastroent Hepatol 2025; 79(1): 37-42
Category:
IBD: Case Report
doi:
https://doi.org/10.48095/ccgh202537
Sources
1. Colwill M, Baillie S, Clough J et al. Role of Mirikizumab in the treatment of inflammatory bowel disease. From bench to bedside. J Clin Med 2025; 14 (3): 1001. doi: https: //doi.org/10.3390/jcm14031001.
Doručeno/Submitted: 15. 1. 2025
Přijato/Accepted: 7. 2. 2025
Korespondenční autor
prof. MUDr. Milan Lukáš, CSc., AGAF
Klinické a výzkumné centrum pro střevní záněty
Klinické centrum ISCARE a. s. a 1. LF UK v Praze
Českomoravská 19
190 00 Praha 9
milan.lukas@email.cz
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2025 Issue 1
- Metamizole vs. Tramadol in Postoperative Analgesia
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
- Safety and Tolerance of Metamizole in Postoperative Analgesia in Children
Most read in this issue
- Current problems in the care of patients with inflammatory bowel disease in the Czech Republic
- IBD is a disease of body and soul
- Iron carboxymaltose in the treatment of iron deficiency/ anaemia in patients with IBD
- The most common psychiatric disorders in patients with inflammatory bowel disease